Clinical Associate Professor John Gibson

• Publications

Publications

2009

Burgess, P, Robin, H, Langshaw, M, Kershaw, G, Pathiraja, R, Yuen, S, Coad, C, Xiros, N, Mansy, G, Coleman, R, Brown, R, Gibson, J, Holman, R, Hubbard, J, Wick, V, Lammers, M, Johnson, R, Huffman, K, Bell, J, Ibrahim, A, Estepa, F, Lovegrove, J, Joshua, D. Rule based processing of the CD4000, CD3200 and CD Sapphire analyser output using the Cerner Discern Expert Module. International journal of laboratory hematology. 2009; 31:603-14

Brown, R, Spencer, A, Ho, P, Kennedy, N, Kabani, K, Yang, S, Sze, D, Aklilu, E, Gibson, J, Joshua, D. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leukemia and Lymphoma. 2009; 50:1860-1864

2008

Bashey, A, Pérez, W, Zhang, M, Anderson, K, Ballen, K, Berenson, J, To, L, Fonseca, R, Freytes, C, Gale, R, Gibson, J, Giralt, S, Kyle, R, Lazarus, H, Maharaj, D, McCarthy, P, Milone, G, Nimer, S, Pavlovsky, S, Reece, D, Schiller, G, Vesole, D, Hari, P, , P. Comparison of twin and autologous transplants for multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008; 14:1118-1124

Kumar, S, Pérez, W, Zhang, M, Ballen, K, Bashey, A, To, L, Bredeson, C, Cairo, M, Elfenbein, G, Freytes, C, Gale, R, Gibson, J, Kyle, R, Lacy, M, Lazarus, H, McCarthy, P, Milone, G, Moreb, J, Pavlovsky, S, Reece, D, Vesole, D, Wiernik, P, Hari, P. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008; 14:1134-1140

Joshua, D, Brown, R, Ho, P, Gibson, J. Regulatory T cells and Multiple Myeloma. Clinical Lymphoma & Myeloma. 2008; 8:283-286

2007

Sanders, J, Crawford, B, Gibson, J, Joy Ho, P, Iland, H, Joshua, D. Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International journal of laboratory hematology. 2007. p. 395-397.

Feyler, S, Prince, H, Pearce, R, Towlson, K, Nivison-Smith, I, Schey, S, Gibson, J, Patton, N, Bradstock, K, Marks, D, Cook, G. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone marrow transplantation. 2007; 40:443-450

Grigg, A, Gibson, J, Bardy, P, Reynolds, J, Shuttleworth, P, Koelmeyer, R, Szer, J, Roberts, A, To, L, Kennedy, G, Bradstock, K. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2007; 13:560-567

Gibson, J, Ho, P, Brown, R, Joshua, D, Sze, D. The role of T-cells in myeloma. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 2007; 92:11-12

2006

Anagnostopoulos, A, Hari, P, Perez, W, Ballen, K, Bashey, A, Bredeson, C, Freytes, C, Gale, R, Gertz, M, Gibson, J, Goldschmidt, H, Lazarus, H, McCarthy, P, Reece, D, Vesole, D, Giralt, S. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biology of Blood and Marrow Transplantation. 2006; 12:845-854

Sze, D, Brown, R, Yang, S, Ho, P, Gibson, J, Joshua, D. The use of thalidomide in myeloma therapy as an effective anticancer drug. Current cancer drug targets. 2006; 6:325-31

Ling, S, Joshua, D, Gibson, J, Young, G, Iland, H, Watson, G, Ho, P. Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?. American journal of hematology. 2006; 81:110-4

2005

Spencer, A, Horvath, N, Gibson, J, Prince, H, Herrmann, R, Bashford, J, Joske, D, Grigg, A, McKendrick, J, Prosser, I, Lowenthal, R, Deveridge, S, Taylor, K, , A. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone marrow transplantation. 2005; 35:971-7

Ling, S, Campbell, L, Ho, J, Gibson, J, Joshua, D. Multiple myeloma: molecular biology, pathology and cytogenetics. In: Clinical Malignant Haematology. New York: McGraw-Hill 2005. p. ?.

2004

Mollee, P, Arthur, C, Hughes, T, Januszewicz, H, Grigg, A, Bradstock, K, Wolf, M, Gibson, J, Schwarer, A, Spencer, A, Browett, P, Hawkins, T, Seldon, M, Herrmann, R, Watson, A, Seymour, J, Martin, N, Shina, S, Low, C, Wright, S, Rodwell, R, Coulston, J, Morton, J, Blacklock, H, Taylor, D, Taylor, K. Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2004; 15:1810-5

Gibson, J, Ho, P, Joshua, D. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic. Transplantation proceedings. 2004; 36:2501-3

Gibson, J, Ho, P, Joshua, D. Low-grade lymphoma: the optimal timing. Transplantation proceedings. 2004; 36:1995-8

Brown, R, Murray, A, Pope, B, Sze, D, Gibson, J, Ho, P, Hart, D, Joshua, D. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. British journal of haematology. 2004; 125:743-8

Horvath, N, Hahn, U, Joshua, D, Dyson, P, Gibson, J, Stevens, J, Rawling, T, Barrow, L, Brown, R, Stephens, S, Gower, G, Norman, J, Mills, B, To, L. Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach. Internal medicine journal. 2004; 34:167-75

Szer, J, Durrant, S, Schwarer, A, Bradstock, K, Gibson, J, Arthur, C, To, L, Hughes, T, Raunow, H. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. Internal medicine journal. 2004; 34:98-101

Brown, R, Murray, A, Pope, B, Sze, D, Gibson, J, Ho, P, Joshua, D. B7+ T cells in myeloma: an acquired marker of prior chronic antigen presentation. Leukemia & lymphoma. 2004; 45:363-71

Joshua, D, Joshua, D, Gibson, J, Ho, P, brown, R. The immune system in myeloma. In: Multiple myeloma and related disorders. UK: Arnold 2004. p. 29-46.

2003

Barrow, L, Brown, R, Murray, A, Sze, D, Pope, B, Gibson, J, Hart, D, Joshua, D. CMRF44+ dendritic cells from peripheral blood stem cell harvests of patients with myeloma as potential cellular vectors for idiotype vaccination. Leukemia and Lymphoma. 2003; 44:2117-2122

Sze, D, Brown, R, Yuen, E, Gibson, J, Ho, J, Raitakari, M, Basten, A, Joshua, D, Fazekas de St Groth, B. Clonal cytotoxic T cells in myeloma. Leukemia & lymphoma. 2003; 44:1667-1674

Szea, D, Brown, R, Yang, S, Gibson, J, Ho, J, Fazekas de St Groth, B, Basten, A, Joshua, D. Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leukemia & lymphoma. 2003; 44:1557-1568

Raitakari, M, Brown, R, Gibson, J, Joshua, D. T cells in myeloma. Hematological Oncology. 2003; 21:33-42

Van Besien, K, Gibson, J, 19 Researchers from, P. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003; 102:2521-2529

2001

Brown, R, Pope, B, Murray, A, Esdale, W, Sze, D, Gibson, J, Ho, P, Hart, D, Joshua, D. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 2001; 98:2992-2998

Sze, D, Giesajtis, G, Brown, R, Raitakari, M, Gibson, J, Ho, J, Baxter, A, Fazekas de St Groth, B, Basten, A, Joshua, D. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood. 2001; 98:2817-2827

Nivison-Smith, I, Bradstock, K, Szer, J, Durrant, S, Dodds, A, Hermann, R, Schwarer, A, Gibson, J, To, L, Arthur, C, , A. Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow. Bone marrow transplantation. 2001; 28:21-7

Ho, P, Brown, R, Pelka, G, Basten, A, Gibson, J, Joshua, D. Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. Blood. 2001; 97:490-5